Header Logo

Connection

Shan Lu to AIDS Vaccines

This is a "connection" page, showing publications Shan Lu has written about AIDS Vaccines.
Connection Strength

6.569
  1. Wang S, Chan KW, Wei D, Ma X, Liu S, Hu G, Park S, Pan R, Gu Y, Nazzari AF, Olia AS, Xu K, Lin BC, Louder MK, McKee K, Doria-Rose NA, Montefiori D, Seaman MS, Zhou T, Kwong PD, Arthos J, Kong XP, Lu S. Human CD4-binding site antibody elicited by polyvalent DNA prime-protein boost vaccine neutralizes cross-clade tier-2-HIV strains. Nat Commun. 2024 May 21; 15(1):4301.
    View in: PubMed
    Score: 0.882
  2. Wang S, Voronin Y, Zhao P, Ishihara M, Mehta N, Porterfield M, Chen Y, Bartley C, Hu G, Han D, Wells L, Tiemeyer M, Lu S. Glycan Profiles of gp120 Protein Vaccines from Four Major HIV-1 Subtypes Produced from Different Host Cell Lines under Non-GMP or GMP Conditions. J Virol. 2020 03 17; 94(7).
    View in: PubMed
    Score: 0.660
  3. Wang S, Chou TH, Hackett A, Efros V, Wang Y, Han D, Wallace A, Chen Y, Hu G, Liu S, Clapham P, Arthos J, Montefiori D, Lu S. Screening of primary gp120 immunogens to formulate the next generation polyvalent DNA prime-protein boost HIV-1 vaccines. Hum Vaccin Immunother. 2017 12 02; 13(12):2996-3009.
    View in: PubMed
    Score: 0.556
  4. Buglione-Corbett R, Pouliot K, Marty-Roix R, Li W, West K, Wang S, Morelli AB, Lien E, Lu S. Reduced MyD88 dependency of ISCOMATRIX? adjuvant in a DNA prime-protein boost HIV vaccine. Hum Vaccin Immunother. 2014; 10(4):1078-90.
    View in: PubMed
    Score: 0.433
  5. Lu S, Grimes Serrano JM, Wang S. Polyvalent AIDS vaccines. Curr HIV Res. 2010 Dec; 8(8):622-9.
    View in: PubMed
    Score: 0.347
  6. Vaine M, Wang S, Liu Q, Arthos J, Montefiori D, Goepfert P, McElrath MJ, Lu S. Profiles of human serum antibody responses elicited by three leading HIV vaccines focusing on the induction of Env-specific antibodies. PLoS One. 2010 Nov 09; 5(11):e13916.
    View in: PubMed
    Score: 0.345
  7. Vaine M, Wang S, Hackett A, Arthos J, Lu S. Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity. Vaccine. 2010 Apr 09; 28(17):2999-3007.
    View in: PubMed
    Score: 0.328
  8. Lu S. Immunogenicity of DNA vaccines in humans: it takes two to tango. Hum Vaccin. 2008 Nov-Dec; 4(6):449-52.
    View in: PubMed
    Score: 0.302
  9. Wang S, Kennedy JS, West K, Montefiori DC, Coley S, Lawrence J, Shen S, Green S, Rothman AL, Ennis FA, Arthos J, Pal R, Markham P, Lu S. Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine. 2008 Jul 23; 26(31):3947-57.
    View in: PubMed
    Score: 0.294
  10. Vaine M, Wang S, Crooks ET, Jiang P, Montefiori DC, Binley J, Lu S. Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination. J Virol. 2008 Aug; 82(15):7369-78.
    View in: PubMed
    Score: 0.291
  11. Wang S, Kennedy JS, West K, Montefiori DC, Coley S, Lawrence J, Shen S, Green S, Rothman AL, Ennis FA, Arthos J, Pal R, Markham P, Lu S. Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine. 2008 Feb 20; 26(8):1098-110.
    View in: PubMed
    Score: 0.284
  12. Wang S, Pal R, Mascola JR, Chou TH, Mboudjeka I, Shen S, Liu Q, Whitney S, Keen T, Nair BC, Kalyanaraman VS, Markham P, Lu S. Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E. Virology. 2006 Jun 20; 350(1):34-47.
    View in: PubMed
    Score: 0.252
  13. Wang S, Farfan-Arribas DJ, Shen S, Chou TH, Hirsch A, He F, Lu S. Relative contributions of codon usage, promoter efficiency and leader sequence to the antigen expression and immunogenicity of HIV-1 Env DNA vaccine. Vaccine. 2006 May 22; 24(21):4531-40.
    View in: PubMed
    Score: 0.240
  14. Wang S, Arthos J, Lawrence JM, Van Ryk D, Mboudjeka I, Shen S, Chou TH, Montefiori DC, Lu S. Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1. J Virol. 2005 Jun; 79(12):7933-7.
    View in: PubMed
    Score: 0.237
  15. Liu F, Mboudjeka I, Shen S, Chou TH, Wang S, Ross TM, Lu S. Independent but not synergistic enhancement to the immunogenicity of DNA vaccine expressing HIV-1 gp120 glycoprotein by codon optimization and C3d fusion in a mouse model. Vaccine. 2004 Apr 16; 22(13-14):1764-72.
    View in: PubMed
    Score: 0.219
  16. Li H, Wang S, Hu G, Zhang L, Liu S, Lu S. DNA priming immunization is more effective than recombinant protein vaccine in eliciting antigen-specific B cell responses. Emerg Microbes Infect. 2021 Dec; 10(1):833-841.
    View in: PubMed
    Score: 0.186
  17. Costa MR, Pollara J, Edwards RW, Seaman MS, Gorny MK, Montefiori DC, Liao HX, Ferrari G, Lu S, Wang S. Fc Receptor-Mediated Activities of Env-Specific Human Monoclonal Antibodies Generated from Volunteers Receiving the DNA Prime-Protein Boost HIV Vaccine DP6-001. J Virol. 2016 Nov 15; 90(22):10362-10378.
    View in: PubMed
    Score: 0.131
  18. Pouliot K, Buglione-Corbett R, Marty-Roix R, Montminy-Paquette S, West K, Wang S, Lu S, Lien E. Contribution of TLR4 and MyD88 for adjuvant monophosphoryl lipid A (MPLA) activity in a DNA prime-protein boost HIV-1 vaccine. Vaccine. 2014 Sep 03; 32(39):5049-56.
    View in: PubMed
    Score: 0.111
  19. Wang S, Kishko M, Wan S, Wang Y, Brewster F, Gray GE, Violari A, Sullivan JL, Somasundaran M, Luzuriaga K, Lu S. Pilot study on the immunogenicity of paired Env immunogens from mother-to-child transmitted HIV-1 isolates. Hum Vaccin Immunother. 2012 Nov 01; 8(11):1638-47.
    View in: PubMed
    Score: 0.099
  20. Abdel-Motal UM, Wang S, Awad A, Lu S, Wigglesworth K, Galili U. Increased immunogenicity of HIV-1 p24 and gp120 following immunization with gp120/p24 fusion protein vaccine expressing alpha-gal epitopes. Vaccine. 2010 Feb 17; 28(7):1758-65.
    View in: PubMed
    Score: 0.081
  21. Lu S. Heterologous prime-boost vaccination. Curr Opin Immunol. 2009 Jun; 21(3):346-51.
    View in: PubMed
    Score: 0.078
  22. Vaine M, Lu S, Wang S. Progress on the induction of neutralizing antibodies against HIV type 1 (HIV-1). BioDrugs. 2009; 23(3):137-53.
    View in: PubMed
    Score: 0.076
  23. Kennedy JS, Co M, Green S, Longtine K, Longtine J, O'Neill MA, Adams JP, Rothman AL, Yu Q, Johnson-Leva R, Pal R, Wang S, Lu S, Markham P. The safety and tolerability of an HIV-1 DNA prime-protein boost vaccine (DP6-001) in healthy adult volunteers. Vaccine. 2008 Aug 18; 26(35):4420-4.
    View in: PubMed
    Score: 0.073
  24. Abdel-Motal U, Wang S, Lu S, Wigglesworth K, Galili U. Increased immunogenicity of human immunodeficiency virus gp120 engineered to express Galalpha1-3Galbeta1-4GlcNAc-R epitopes. J Virol. 2006 Jul; 80(14):6943-51.
    View in: PubMed
    Score: 0.064
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.